On 11 January 2022, the European Commission and MHRA approved Kaftrio for eligible children aged 6-11 in England, Scotland, Wales and Northern Ireland.

See CF trust update for more information. We will be in touch with those eligible to arrange all tests needed to prescribe and discuss with you what this means for you

Toggle search Open search menu icon SEARCH THE SITE Open contact page icon Contact Parking icon Find & Parking
Royal Devon and Exeter NHS logo

CF Related Diabetes

Cystic fibrosis-related diabetes (CFRD)  is common in adults and adolescents with cystic fibrosis. Approximately one-third of people with CF aged 16 and over are being treated for CFRD in the UK compared to 11% of children aged 10–15 years (UK CF registry data).

CFRD is different from type 1 and type 2 diabetes, but has features of both. If untreated, high blood glucose levels can cause complications such as weight loss, recurrent chest infections, reduced lung function, kidney damage, and problems with eyesight. Early detection and treatment has been shown to have very positive effects on lung function, as well as preventing complications. We screen for CFRD at annual review as well as targeting testing when we suspect it may be a problem.

Please see link to CF Trust factsheet on CFRD for more detailed information and talk to your team if you have any questions.

We work jointly with our Specialist Diabetes colleagues both in adult and Paediatrics to tailor care to your needs so we can look after both your CF and your Diabetes.